Interferon as a Cell Product

  • Jan Vilcek
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 118)


Everyone is aware of the long lag period between the general notion of the clinical potential of interferon, developed some twenty years ago, and the actual application of interferon in clinical practice. Today we are at a stage when practical sources of human interferon for clinical trials are finally being developed and it is becoming possible to produce quantities of interferon that — though still relatively modest — will allow a thorough evaluation of interferon’s clinical potential.


Newcastle Disease Virus Cell Substrate Human Interferon Antiviral State Interferon Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Johnson, H.M., Baron, S. Interferon: Effects on the immune response and the mechanism of activation of the cellular response. CRC Critical Reviews in Biochemistry 4: 203–227, 1976.PubMedCrossRefGoogle Scholar
  2. 2.
    De Maeyer, E., De Maeyer-Guignard, J. Effect of interferon on cell-mediated immunity. Tex. Rep. Biol. Med. 35: 370–374, 1977.PubMedGoogle Scholar
  3. 3.
    Paucker, K., Cantell, K., Henle, W. Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17: 324–334, 1962.Google Scholar
  4. 4.
    Gresser, I., Brouty-Boyé, D, Thomas, M-T, et al. Interferon and cell division. I. Inhibition of the multiplication of mouse leukemia L 1210 cells in vitro by interferon preparations. Proc. Nat. Acad. Sci. 66: 1052–1058, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    Strander, H. Anti-tumour effects of interferon and its possible use as an antineoplastic agent in man. Tex. Rep. Biol. Med. 35: 429–435. 1977.PubMedGoogle Scholar
  6. 6.
    Rivière, Y., Gresser, I., Guillon, J-T., et al. Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice. Proc. Nat. Acad. Sci. USA 74:2135–2139. 1977.PubMedCrossRefGoogle Scholar
  7. 7.
    Ida, S., Hooks, J.J., Siraganian, R.P., et al. Enhancement of IgE-mediated histamine release from human basophils by viruses: Rose of interferon. J, Exp. Med. 145: 892–906. 1977.CrossRefGoogle Scholar
  8. 8.
    Wietzerbin, J., Stefanos, S., Falcoff, R., et al. Immune interferon induced by phytohemagglutinin in nude mouse spleen cells. Infect. Immun. 21: 966–972. 1978.PubMedGoogle Scholar
  9. 9.
    Vilcek, J,, Havell, E.A., Yamazaki, S. Antigenic, physico-chemical and biological characterization of human interferons. Ann. N.Y. Acad. Sci. 284: 703–710. 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    Havell, E.A., Berman, B., Ogburn, C.A., et al. Two antigenical-ly distinct species of human interferon. Proc. Nat. Acad. Sci. USA. 72: 2185–2187. 1975.PubMedCrossRefGoogle Scholar
  11. 11.
    Havell, E.A., Hayes, T.G., Vilcek, J. Synthesis of two distinct interferons by human fibroblasts. Virology 89: 330–334. 1978.PubMedCrossRefGoogle Scholar
  12. 12.
    Mogensen, K.E., Cantell, K. Stability of human leukocyte interferon towards heat. Acta Path. Microbiol. Scand. B. 81: 382–383. 1973.Google Scholar
  13. 13.
    Stewart, W. E. II, De Clercq, E., De Somer, P. Stabilisation of interferons by defensive reversible denaturation. Nature 249: 460–461. 1974.PubMedCrossRefGoogle Scholar
  14. 14.
    Sonnenfeld, G., Mandel A.D., Merigan, T.C. Immunomodulating activitiy and characterization of type II interferon. Fed. Proc. 36: 1229. 1977.Google Scholar
  15. 15.
    Gardner, L.J., Vilcek, J. Initial interaction of human fibroblast and leukocyte interferons with FS-4 fibroblasts. J. Gen. Virol. (in press).Google Scholar
  16. 16.
    Einhorn, S., Strander, H. Is interferon tissue specific?-Effect of human leukocyte and fibroblast interferons on the the growth of lymphoblastoid and osteosarcoma cell lines. J. Gen. Virol. 35: 573–577. 1977.PubMedCrossRefGoogle Scholar
  17. 17.
    Kuwata, T., Fuse, A., Suzuki, et al. Comparison of suppression of cell and virus growth in human transformed cells by leukocyte and fibroblast interferon. J. Gen. Virol. (in press).Google Scholar
  18. 18.
    Cantell, K., Pyhälä, L., Strander, H. Circulating human interferon after intramuscular injection into animals and man. J. Gen. Virol. 22: 453–455. 1974.CrossRefGoogle Scholar
  19. 19.
    Jordan, G.W., Fried, R.P., Merigan, T.C. Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating antiviral activity and host responses to infection. J. Inf. Dis. 130: 56–62. 1974.Google Scholar
  20. 20.
    Weimar, W., Heitjink, R.A., Schalm, S.W. et al. Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet ii: 1282. 1977.Google Scholar
  21. 21.
    Harmon, M., Greenberg, S., Couch, R. Effect of human nasal secretions on the antiviral activity of human fibroblast and leukocyte interferon. Proc. Soc. Exp. Biol. Med. 152: 598–602. 1976.PubMedGoogle Scholar
  22. 22.
    Cesario, T.C., Tilles., J.G. Inactivation of human interferon by body fluids. Tex. Rep. Biol. Med. 35: 443–448. 1977.PubMedGoogle Scholar
  23. 23.
    Strander, H., Cantell, K. Production of interferon by human leukocytes in vitro. Ann. Med. Exp. Biol. Fenn. 44: 265–273. 1966.PubMedGoogle Scholar
  24. 24.
    Cantell, K., Hirvonen, S., Mogensen, K.E. et al. Human leukocyte interferon: Production, purification, stability, and animal experiments. The Production and Use of Interferon for the Treatment and Prevention of Human Virus Infections-In vitro. Edited by C. Waymouth. Monograph no. 3, pp/ 35–38. 1974.Google Scholar
  25. 25.
    Cantell, K. Hirvonen, S. Large-scale production of human leukocyte interferon containing 108 units per ml. J. Gen. Virol. 39: 541–543. 1978.PubMedCrossRefGoogle Scholar
  26. 26.
    Strander, H., Mogensen, K.E., Cantel, K. Production of human lymphoblastoid interferon. J. Clin. Microbiol. 1: 116–117. 1975.PubMedGoogle Scholar
  27. 27.
    Zoon, K.C., Buckler, C.E. Bridgen, P.J. et al. Production of human lymphoblastoid interferon by Namalva cells. J. Clin. Microbiol. 7: 44–51. 1978.PubMedGoogle Scholar
  28. 28.
    De Ley, M., Billiau, A., De Somer, P. A semi-continuous system for the production of human interferon in lymphoblastoid cell cultures. J. Gen. Virol. 40: 455–458. 1978.PubMedCrossRefGoogle Scholar
  29. 29.
    Havell, E.A., Yip, Y.K., Vilček, J. Characteristics of human lymphoblastoid (Namalva) interferon. J. Gen. Virol. 38: 51–59, 1977.CrossRefGoogle Scholar
  30. 30.
    Billiau, A,, Joniau, M,, De Somer, P, Mass production of human interferon in diploid cells stimulated by poly I:C. J. Gen. Virol. 19: 1–8. 1973.PubMedCrossRefGoogle Scholar
  31. 31.
    Havell, E.A., Vilček, J. Production of high-titered interferon in cultured of human diploid cells. Antimicrob. Ag. Chemother. 2: 476–484. 1972.Google Scholar
  32. 32.
    Mozes, L.W., Havell, E.A., Gradoville, M.L. et al. increased interferon in human cells irradiated with ultraviolet light. Infec. Immun. 10: 1189–1191. 1974.Google Scholar
  33. 33.
    Vilček, J., Havell, E.A., Gradoville, M.L. et al. Selection of new human foreskin fibroblast cell strains for interferon production. Human Interferon, Production and Clinical Use. Edited by W. R. Stinebring, P. J. Chappie. New York, Plenum Press, pp. 101–118. 1978.Google Scholar
  34. 34.
    Billiau, A., Edy, V.G., Heremans, H. Human interferon: Mass production in a newly established cell line, MG-63. Antimicrob. Ag. Chemother. 12: 11–15. 1977.Google Scholar
  35. 35.
    Berthold, W., Tan, C., Tan, T.H. Purification and in vitro labeling of interferon from a human fibroblastoid cell line. J. Biol. Chem 253: 5206–5212. 1978.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1979

Authors and Affiliations

  • Jan Vilcek
    • 1
  1. 1.Department of MicrobiologyNew York University School of MedicineNew YorkUSA

Personalised recommendations